Iradimed Corporation will release its 2024 Q4 financial results on February 13, 2025, followed by a conference call.
Quiver AI Summary
Iradimed Corporation announced that it will release its fourth quarter financial results for 2024 on February 13, 2025, before the market opens. Following the release, the management will host a conference call at 11:00 a.m. Eastern Time to discuss the results and answer questions from participants, who can register to join the call via a provided link. Iradimed is recognized for its innovative MRI-compatible medical devices, particularly its non-magnetic IV infusion pump system and the 3880 patient vital signs monitoring system. These products are designed to safely deliver fluids and monitor patients during MRI procedures, addressing the challenges posed by traditional equipment that may interfere with MRI technology. The company emphasizes its commitment to patient safety and effective care in critical situations. For more information, interested parties can visit the Iradimed website.
Potential Positives
- The announcement of the fourth quarter financial results and conference call reflects transparency and communication with investors, which can build trust and confidence in the company's operations.
- As a leader in the development of MRI-compatible medical devices, Iradimed Corporation is positioned in a unique market niche, potentially driving growth and revenue through their innovative products.
- The patented MRidium® MRI compatible IV infusion pump system addresses specific safety concerns during MRI procedures, showcasing the company's commitment to patient safety and innovative solutions in healthcare technology.
- The Iradimed 3880 patient vital signs monitoring system's ability to operate in high magnetic fields and its portable design enhances patient care during MRI procedures, indicating significant advancements in medical technology offerings.
Potential Negatives
- Delayed financial results announcement could indicate potential issues or concerns about the company's performance in the fourth quarter of 2024.
- The use of a conference call for discussing results may suggest that management anticipates difficult questions from analysts or investors.
FAQ
When will Iradimed release its fourth quarter financial results?
Iradimed will release its 2024 fourth quarter financial results on February 13, 2025, before the market opens.
How can I participate in Iradimed's conference call?
Interested individuals can register for the conference call at https://register.vevent.com/register/BI94f1f3be82df46ccb09997e06cb41e49.
What is the purpose of Iradimed's conference call?
The conference call will discuss Iradimed's fourth quarter financial results and answer participant questions.
Where can I find the recording of the conference call?
A recording of the conference call will be available on Iradimed's website following the call.
What is unique about Iradimed's MRI compatible devices?
Iradimed offers non-magnetic IV infusion pumps and vital signs monitoring systems specifically designed for safe MRI use.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRMD Insider Trading Activity
$IRMD insiders have traded $IRMD stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $IRMD stock by insiders over the last 6 months:
- ANTHONY VUOTO sold 2,690 shares for an estimated $150,616
- JOHN GLENN (CHIEF FINANCIAL OFFICER) sold 2,500 shares for an estimated $135,449
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IRMD Hedge Fund Activity
We have seen 78 institutional investors add shares of $IRMD stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RK CAPITAL MANAGEMENT, LLC removed 170,084 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $8,553,524
- BLACKROCK, INC. added 121,394 shares (+14.8%) to their portfolio in Q3 2024, for an estimated $6,104,904
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 102,067 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,132,949
- GOLDMAN SACHS GROUP INC added 77,956 shares (+98.7%) to their portfolio in Q3 2024, for an estimated $3,920,407
- TEACHER RETIREMENT SYSTEM OF TEXAS added 56,733 shares (+423.1%) to their portfolio in Q3 2024, for an estimated $2,853,102
- COPELAND CAPITAL MANAGEMENT, LLC added 53,138 shares (+12.6%) to their portfolio in Q4 2024, for an estimated $2,922,590
- VANGUARD GROUP INC added 44,966 shares (+9.6%) to their portfolio in Q3 2024, for an estimated $2,261,340
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here,
https://register.vevent.com/register/BI94f1f3be82df46ccb09997e06cb41e49
Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/ . A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
[email protected]